Microdose or Mirage? What the Randomized Evidence Actually Shows
A small dose with an enormous reputation
Microdosing usually means taking a sub-hallucinogenic amount of a psychedelic such as LSD or psilocybin on intermittent days. Its modern appeal is easy to understand. The dose is presented as small enough to preserve ordinary functioning, yet potentially large enough to improve mood, creativity, focus, or emotional flexibility.
The stories are compelling. They are also difficult to interpret. Someone who begins microdosing may simultaneously sleep differently, pay closer attention to mood, change exercise or meditation habits, or expect improvement. If they know—or strongly suspect—that they received the active drug, expectancy itself can shape what they notice and report.
Shakila Meshkat and colleagues therefore asked an important question: what happens when the entire literature is considered, and randomized studies are separated from observational ones?
What the researchers reviewed
The authors searched Embase, MEDLINE, and PsycINFO through February 2026. They included 24 studies with 3,681 participants. The population was healthy or non-clinical adults rather than patients receiving treatment for a diagnosed psychiatric disorder.
The review included randomized trials, nonrandomized prospective studies, cross-sectional studies, and observational longitudinal designs. Six studies contributed to meta-analyses. For the main randomized efficacy estimates, however, the evidence was much smaller: two parallel randomized trials, comprising three comparisons and 117 participants. Safety analyses included two randomized trials with 109 participants.
That distinction matters. “Twenty-four studies” sounds substantial; the placebo-controlled evidence capable of addressing efficacy was limited.
What the results showed
Randomized studies found subjective and neurophysiological effects from low-dose LSD or psilocybin, but little consistent improvement in cognition, creativity, sustained mood, or personality.
In pooled randomized analyses, there was no clear immediate benefit for depressive symptoms (standardized mean difference −0.19; 95% confidence interval −0.56 to 0.19), anxiety (−0.20; 95% CI −1.11 to 0.71), or stress (0.02; 95% CI −0.39 to 0.43). Each interval crossed zero. Adverse-event risk was similar between treatment and control groups in the available randomized data.
Some observational studies reported improvements in mood or personality. Yet these studies are especially vulnerable to expectancy, selection, lifestyle differences, and regression toward the mean. Exploratory analyses combining different study designs suggested possible improvement in depressive symptoms and stress, but mixing randomized and nonrandomized evidence cannot create the protection from bias that randomization provides.
What the paper does not prove
The review does not establish that microdosing “does nothing.” The randomized evidence was too small for that conclusion. Wide confidence intervals leave room for modest benefit, no benefit, or—in some outcomes—possible harm.
It also does not address full-dose psychedelic-assisted therapy delivered with preparation, clinical monitoring, and psychological support. That is a different intervention, usually studied in clinical populations. Findings about healthy adults taking repeated sub-hallucinogenic doses should not be used to dismiss or validate therapeutic-dose research.
Long-term safety also remains uncertain. Similar short-term adverse-event rates are reassuring only within the narrow exposures and sample sizes studied.
Why expectancy belongs in the story
Placebo effects are not imaginary. Expectations can change attention, interpretation, behavior, and even measurable symptoms. But a treatment claim becomes clinically meaningful only when improvement can be shown beyond those influences and weighed against cost, risk, and alternatives.
Microdosing presents an unusually difficult test because the intervention is culturally loaded and the subjective effects may reveal treatment assignment. Better trials will need adequate sample sizes, credible blinding, prespecified outcomes, longer follow-up, and transparent reporting of whether participants correctly guessed what they received.
The most useful conclusion
The current evidence supports neither ridicule nor evangelism. It supports precision.
People may sincerely experience improvement while microdosing. The available randomized trials have not yet shown that the drug itself produces clear immediate reductions in depression, anxiety, or stress among healthy adults. That gap between experience and evidence is not a verdict. It is the question future research must answer.
Comments